Acute exacerbation is also a good indication for the application of recombinant human TRX in COPD management to control enhanced inflammation, whereas other dosage forms, such as inhalation and oral administration of a TRX inducer, must be evaluated in the stable phase of COPD in future studies. This evidence concerns the gene TXN and chronic obstructive pulmonary disease.